White papers
Latest White Papers, Product Announcements and News…
_____________________________________________________________________
Quotient Bioresearch is a leading provider of early stage and specialist drug development services to life science clients worldwide.
Biomarkers are now an integral part of industry efforts to streamline drug development. They are increasingly important in helping “go/no go” decisions in early phase preclinical and clinical development, either as indicators of safety or efficacy. We provide a breadth of capabilities and choice, spanning biomarker discovery, assay development, validation and sample analysis supporting preclinical and clinical development programmes. Download a copy of our Biomarkers in Rheumatoid Arthritis (RA) white paper to gain Insightful information on biomarkers for drug discovery and development.
_____________________________________________________________________
Banyan Biomarkers is the leader in developing in vitro diagnostic products to address unmet clinical needs in acute neurological injury and neurological disease. The Company is focused on developing a simple point-of-care blood test to detect the presence and severity of brain trauma and improve the medical management of head injured patients.
_____________________________________________________________________
Almac is a personalised medicine company which partners with the biopharmaceutical industry to provide biomarker solutions, ranging from pre-clinical biomarker discovery, through to full companion diagnostic development and clinical test delivery from our CLIA lab.
www.almacgroup.com/biomarker-discovery-development
Click the icon to read the Almac paper, “Personalised Medicine from Concept to Clinical use”
_____________________________________________________________________
OracleBio offers digital image analysis of histological tissue sections for biomarker and morphological profiling using Definiens state of the art Tissue Studio™ software. Visit our website to learn more about our image analysis capabilities, biomarker study management and biomarker consultancy services at www.oraclebio.com
_____________________________________________________________________
HLS Biomarkers and Translational Sciences supports your drug development needs by providing a range of biomarker services including assay development, validation and testing, from early Research to Clinical translation. Contact us to find out how we can help you in compound selection, dose optimisation, efficacy, safety monitoring and patient stratification.
_____________________________________________________________________
At Tissue Solutions, our goal is to provide high quality, well-characterized and ethically sourced tissue and biofluid samples for all your biomarker needs, to your exact specifications. We specialise in the “harder” to source biomaterials and custom collections in Oncology, Autoimmune, CNS/Neurodegenerative, Inflammation, Metabolic, Cardiovascular and Infectious Diseases.
_____________________________________________________________________
At Innogenetics, an international diagnostic company based in Ghent (Belgium) and part of the Fujirebio group, we have been actively engaged in AD biomarker development for the past decade. Our current panel of biomarkers – beta-amyloid (Aβ), tau, and phosphorylated tau proteins, measured in cerebrospinal fluid (CSF), by enzyme-linked immunosorbent assays (INNOTEST® ELISA microplate) is the most extensively studied set of biomarkers to date.
Click the icon to download the Innogenetics white paper, “CSF biological markers for the diagnosis of Alzheimer’s disease”
_____________________________________________________________________
Biomarker News from Eurofins Global Central Laboratory
Eurofins now supports:
Assessment of early signs of Nephrotoxicity in Drug Development: method validation for the quantification of urinary KIM-1 and Cystatin-C.
and
Calprotectin in biomarker-mediated drug development: Method validation for the quantification of fecal Calprotectin.
Click here for scientific posters about these biomarker tools
Dr. Edwin Janssen will elaborate the case study on Calprotectin in his presentation on Day 2 – 11:50. We welcome you to join this talk.
More biomarker-mediated drug development
• PD – target engagement biomarkers, proof-of-mechanism and proof-of-concept studies
• Feasibility assessment and scientific consultation
• Fit-for-purpose validation and analysis of commercially available biomarker assays
• Biomarkers for kidney injury
• Biomarkers in exotic matrices (e.g. sputum, stool)
Read more or Contact us at biomarkers@eurofins.com
   
|